Listing of the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (ORIGINAL) A device comprising an extracellular matrix having an internal pH between 4.0 and 6.0, wherein the extracellular matrix contains heparin or a heparin-related compound bound to a protein, wherein the protein has a pH dependent binding to the heparin or the heparin-related compound.

2. (ORIGINAL) The device of claim 1, wherein the internal pH is between 5 and 6.

3. (ORIGINAL) The device of claim 1, wherein the internal pH is about 5.5.

4. (ORIGINAL) The device of claim 1, wherein the bound protein is VEGF.

5. (PREVIOUSLY PRESENTED) The device of claim 1, wherein the extracellular matrix further comprises fibronectin or a fibronectin fragment that binds to the bound protein.

6. (CANCELED)

7. (ORIGINAL) The device of claim 1, wherein the heparin-related compound is heparan sulfate or heparan sulfate proteoglycan.

8. (PREVIOUSLY PRESENTED) The device of claim 1, wherein the bound protein contains a heparin-binding consensus sequence.

9. (ORIGINAL) The device of claim 8, wherein the heparin-binding consensus sequence is XBBBXXBX or XBBXBX, where B is a basic amino acid residue or His and X is any amino acid residue.

10. (PREVIOUSLY PRESENTED) The device of claim 1, wherein the bound protein contains a glycine-like box, wherein said glycine-like box is from about seven to twelve amino acids and contains at least two Gly residues and two-five basic amino acid residues.

11. (ORIGINAL) The device of claim 1, wherein the glycine-like box is SEQ ID NO:1.

12. (ORIGINAL) The device of claim 11, wherein the bound protein is VEGF121 or VEGF165.

13. (PREVIOUSLY PRESENTED) The device of claim 1, wherein the device is formed in situ in a subject.

14. (PREVIOUSLY PRESENTED) A kit for making the device of claim 1, wherein the kit contains a vial containing heparin or a heparin-related compound and a second vial containing fibronectin or a protein containing a heparin-bind domain.

15. (PREVIOUSLY PRESENTED) The device of claim 1, wherein the extracellular matrix is attached to or encased within a compound selected from the group consisting of a film, a hydrocolloid, a hydrogel, a foam, a gelatin, a bead, a bandage, and a cellophane.

16. (PREVIOUSLY PRESENTED) The device of claim 1, wherein the heparin-related compound is a heparin-related oligiosaccharide of 8-16 sugars.

17-22. (CANCELED)

23. (PREVIOUSLY PRESENTED) The device of claim 4, wherein the extracellular matrix further comprises fibronectin or a fibronectin fragment that binds to the bound protein.

24. (PREVIOUSLY PRESENTED) The device of 4, wherein the bound protein contains a heparin-binding consensus sequence.

25. (PREVIOUSLY PRESENTED) The device of 4, wherein the bound protein contains a glycine-like box, wherein said glycine-like box is from about seven to twelve amino acids and contains at least two Gly residues and two-five basic amino acid residues.

26. (PREVIOUSLY PRESENTED) The device of 7, wherein the bound protein contains a glycine-like box, wherein said glycine-like box is from about seven to twelve amino acids and contains at least two Gly residues and two-five basic amino acid residues.

27. (PREVIOUSLY PRESENTED) The device of 4, wherein the device is formed in situ in a subject.

28. (PREVIOUSLY PRESENTED) The device of 7, wherein the device is formed in situ in a subject.

29. (PREVIOUSLY PRESENTED) The device of 12, wherein the device is formed in situ in a subject.

30. (PREVIOUSLY PRESENTED) The method of claim 19, wherein the extracellular matrix further comprises fibronectin or a fibronectin fragment that binds to the bound protein and wherein the heparin-related compound is heparan sulfate or heparan sulfate proteoglycan.